Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Upadacitinib improved multiple immune-related conditions in one patient.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Adalimumab improved folliculitis decalvans in most patients.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Ritlecitinib can help about 14,000 people with severe hair loss.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.